CN1240430C - Medicine for preventing and treating chronic exhaustion syndrome and preparing mthod thereof - Google Patents
Medicine for preventing and treating chronic exhaustion syndrome and preparing mthod thereof Download PDFInfo
- Publication number
- CN1240430C CN1240430C CNB031469671A CN03146967A CN1240430C CN 1240430 C CN1240430 C CN 1240430C CN B031469671 A CNB031469671 A CN B031469671A CN 03146967 A CN03146967 A CN 03146967A CN 1240430 C CN1240430 C CN 1240430C
- Authority
- CN
- China
- Prior art keywords
- medicine
- colla
- chronic fatigue
- fatigue syndrome
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 229940079593 drug Drugs 0.000 title description 7
- 208000011580 syndromic disease Diseases 0.000 title description 3
- 230000001684 chronic effect Effects 0.000 title description 2
- 208000016253 exhaustion Diseases 0.000 title 1
- 239000007788 liquid Substances 0.000 claims abstract description 39
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims abstract description 20
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims abstract description 20
- 241000005787 Cistanche Species 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000003826 tablet Substances 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 241001550206 Colla Species 0.000 claims description 24
- 108010052008 colla corii asini Proteins 0.000 claims description 18
- 241000208340 Araliaceae Species 0.000 claims description 15
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 15
- 235000008434 ginseng Nutrition 0.000 claims description 15
- 241000209020 Cornus Species 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 18
- 238000000034 method Methods 0.000 abstract description 11
- 206010012735 Diarrhoea Diseases 0.000 abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 7
- 208000031975 Yang Deficiency Diseases 0.000 abstract description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 5
- 206010022437 insomnia Diseases 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 206010046543 Urinary incontinence Diseases 0.000 abstract description 4
- 210000003414 extremity Anatomy 0.000 abstract description 4
- 201000001881 impotence Diseases 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000003292 glue Substances 0.000 abstract description 3
- 230000001954 sterilising effect Effects 0.000 abstract description 3
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 3
- 108010010803 Gelatin Proteins 0.000 abstract description 2
- 206010003549 asthenia Diseases 0.000 abstract description 2
- 229920000159 gelatin Polymers 0.000 abstract description 2
- 239000008273 gelatin Substances 0.000 abstract description 2
- 235000019322 gelatine Nutrition 0.000 abstract description 2
- 235000011852 gelatine desserts Nutrition 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 208000031091 Amnestic disease Diseases 0.000 abstract 1
- 239000003390 Chinese drug Substances 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 240000002624 Mespilus germanica Species 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 206010030124 Oedema peripheral Diseases 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 241000270708 Testudinidae Species 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 230000006986 amnesia Effects 0.000 abstract 1
- 210000003056 antler Anatomy 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 206010016256 fatigue Diseases 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000011800 void material Substances 0.000 description 4
- 206010063659 Aversion Diseases 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- 208000019914 Mental Fatigue Diseases 0.000 description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 230000002180 anti-stress Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000012201 sexual and gender identity disease Diseases 0.000 description 3
- 208000015891 sexual disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 208000011726 slow pulse Diseases 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- PCGVPMHGSJFFTI-ZEYGOCRCSA-N (4ar,5as,8ar,13as,15as,15br)-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2h-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinoline-14-one;nitric acid Chemical compound O[N+]([O-])=O.O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 PCGVPMHGSJFFTI-ZEYGOCRCSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010053156 Musculoskeletal discomfort Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940059935 strychnine nitrate Drugs 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019590 thick flavour Nutrition 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention discloses medicine for preventing and treating chronic fatigue syndrome. The present invention uses antler glue, glue of tortoise plastron, donkey-hide gelatin, red ginseng, epimedium, herba cistanches, amomun fruit and medlar as raw materials, the raw materials respectively carry out the treatment such as extraction, etc. by alcohol and water according to different characteristics of each kind of traditional Chinese medicine, then, the raw materials are proportionally prepared, and next, the raw materials are made into Chinese drug preparations such as oral liquid or capsules or tablets, etc. through sterilization. The present invention has a special recipe and a special manufacture method, and has the preeminent effect on preventing and treating the chronic fatigue syndrome with the symptoms such as apocamnosis, weakness of QI, spiritlessness, intolerance of cold, cold limbs, insomnia, amnesia, impotence and seminal emission or yang deficiency without sperm even diarrhea, diarrhea with undigested food or aconuresis or soreness of the waist and kness, edema of lower extremity, pale tongue, slippery tongue fur, slow and sunken pulse and asthenia.
Description
Technical field
The present invention relates to the medicine of a kind of prevention and treatment chronic fatigue syndrome, specifically is the Chinese patent medicine of feedstock production with the Chinese herbal medicine.
Background technology
Chronic fatigue syndrome (chronic fatigue syndrome, CFS) be to cause extremely tiredly with unknown cause, accompanying symptoms such as forgetful, absent minded, throat pain, cervical region or the tenderness of axillary region lymph node, headache, muscle arthralgia, sleep disorder and tired back discomfort to continue half a year above is the clinical syndrome of feature.The Center for Disease Control in 1988 is worked out the CFS diagnostic criteria, 1994 by Fukudak etc. to extensively being approved behind this standard revision.CFS can break out and spread, also can distribute, good sending out in 20～50 years old age group, see with the women more, its cause of disease it be unclear that, may be relevant with viral infection and dysimmunity, and doctor trained in Western medicine lacks effective medicine so far, use the research of Chinese medicine method diagnosis and treatment CFS to obtain significant curative effect at present both at home and abroad to the Drug therapy of primary disease in recent years, have following problem: does not effectively prevent and medicine (1); (2) at present both at home and abroad mainly with the Western medicine symptomatic treatment, but curative effect is difficult to long-term consolidation, and deposits certain side effect and untoward reaction.
Summary of the invention
The object of the present invention is to provide a kind of effective prevention and treatment to show as drained, weakness of QI Mental fatigue, aversion to cold and cold limbs, insomnia forgetfulness; Or impotence and seminal emission, or the sun loss of fecundity that declines, loose stool and diarrhea, very then aqueous-grainy diarrhea, or incontinence of urine, or waist knee joint weakness, edema of lower limbs, light red tongue moist and slippery fur, the medicine of the chronic fatigue syndrome that deep-slow pulse is unable.
Solution of the present invention is based on the understanding of motherland's medical science to chronic fatigue syndrome, chronic fatigue syndrome is typical case's performance of subhealth state, it is one of principal disease of present harm humans health, belong within the disease scopes such as deficient, asthenia in the Chinese medicine, five kinds of strain and seven kinds of impairment, Chinese medicine has accumulated abundant clinical experience to its diagnosis and the history in existing thousands of years of treatment.
Chinese medicine thinks that the etiology and pathogenesis of primary disease is owing to cause a disease or due to illness cause void because of void, thereby makes the internal organs loss, and the negative and positive of qi and blood deficiency finally causes a dirty disease that is subjected to, and it is dirty to involve him; The deficiency of vital energy can not hemopoietic, and blood deficiency is difficult to foster the spirit of nobility; More can cause deficiency of YANG affecting YIN, deficiency of YIN affecting YANG.The yang deficiency syndrome of chronic fatigue syndrome, the kidney being a ZANG-organ containing both water and fire, vigour is gathered, for Yuanyang basic.Insufficiency of kidney-YANG, decline of the fire from the gate of life can not be warm, YANG failing to warm spleen-YANG, thus drained, weakness of QI Mental fatigue, aversion to cold and cold limbs, insomnia forgetfulness, waist knee joint weakness, or diet reduces loose stool; Kidney storing essence, yang deficiency, the yang deficiency fire dysfunction of the kidney in storing essence that declines, smart close solid, so sexual impotence, spermatorrhea are sterile; Unit's YANG deficiency, suffering from a deficiency of the kidney can not astringency inducing, and so the urinary bladder being out of control is incontinence of urine.Method of treatment is when abiding by " interior warp ": " deficiency syndrome should be treated by tonifying method ", " damage person's benefit ", " weakened configuration person, warming with drugs of thick nature; The insufficiency of essence person, tonifying with drugs of thick flavor ".Zhang Jingyue is said " nourishing renal yang to restrict excessive yin is with the be shaded or hidden for foliage that disappears ".The gas of the big complement sun of Fang Zhongyong Radix Ginseng, as the master that the yang deficiency weakness of QI must be thought with Radix Ginseng, the merit of lid Radix Ginseng is then gone into sun with positive medicine and is divided, and then goes into cloudy the branch with cloudy medicine, and desire mends that the gate of vitality's sun is non-not to prove effective with Radix Ginseng.5 with the Herba Epimedii warming and recuperating the kidney-YANG, rouses oneself kidney yang tired out, is to be monarch drug.Minister is with Fructus Lycii nourishing the liver and kidney, replenishing vital essence to improve eyesight; The Herba Cistanches kidney-replenishing, benefiting essence-blood, loosening bowel to relieve constipation.Testudinis deer Ah three glue is the in love product of flesh and blood, high benefit marrow, and with being adjuvant drug, Colla cornus cervi is partial to YANG invigorating, and specially in enriching blood, Colla Plastri Testudinis is partial to nourishing YIN to Colla Corii Asini, and adapted YIN-tonifying drug among YANG invigorating has embodied the theoretical rule for the treatment of YIN within YANG.Said as Ming Dynasty's well-known doctor's Zhang Jingyue: " kind YANG invigorating person must be in treating YIN within YANG, then positive cloudy helping and biochemical infinite ".In nourishing replenishing essence medicine, add simply the Fructus Amomi fragrance warm in nature stomach of being amusing to regulate the flow of vital energy, be intended to prevent the product informal dress that moistens for a long time the clothes spleen that stagnates hinder stomach, cause symptom appearance such as the vexed lack of appetite of gastral cavity.Take a broad view of full side, with the warming YANG kidney tonifying, replenishing essence is enriched blood, disappear tired soothe the spirit be aim, the sun of logical spleen reinforcing kidney be a purpose, makes laws tightly, selects for use medicine precise and appropriate, compatibility is done in the proper way." the empty unit of reason mirror ": " reason void has three, and lung spleen kidney is also, and lung is the sky of the five internal organs, and spleen is the mother of bones of the body collectively, and kidney is the root of the whole body, knows this three, and the road of reason void is finished.
Medicine of the present invention is to be made by following component: (consumption is a weight portion)
Colla cornus cervi 10～18 Colla Plastri Testudinis 10～20 Colla Corii Asini 10～20 Radix Ginseng Rubra 12～18
Herba Epimedii 12～20 Herba Cistanches 10～20 Fructus Amomis 8～12 Fructus Lyciis 8～12.
Formula optimization weight (part) ratio range of preparation medicine of the present invention is:
Colla cornus cervi 12～15 Colla Plastri Testudinis 12～18 Colla Corii Asini 12～15 Radix Ginseng Rubra 15～18
Herba Epimedii 14～16 Herba Cistanches 14～16 Fructus Amomis 8～12 Fructus Lyciis 8～12.
The optimum weight of medicine of the present invention (part) proportioning is:
Colla cornus cervi 15 Colla Plastri Testudinis 15 Colla Corii Asini 15 Radix Ginseng Rubra 15
Herba Epimedii 15 Herba Cistanches 15 Fructus Amomis 10 Fructus Lyciis 10.
The above-mentioned medicine that is used to prevent and treat chronic fatigue syndrome can be made said multiple dosage form on the pharmaceutics, as oral liquid, capsule or tablet.
The method that above-mentioned each component is made medicine of the present invention is:
More than eight flavors, with Colla cornus cervi, after Colla Plastri Testudinis, Colla Corii Asini added water respectively, water proof melted, the cooling back filters, merging filtrate, container is collected; Radix Ginseng Rubra decocts three times after adding the suitable quantity of water immersion, merges three times decocting liquid, cooled and filtered, and container is collected; After Herba Epimedii, Herba Cistanches, Fructus Amomi, Fructus Lycii merging add suitable quantity of water together, decoct three times, merge three times decocting liquid, cooled and filtered, container is collected; Just above-mentioned five parts of medicinal liquids merge together, concentrate, and add ethanol, stir evenly, leave standstill, filter, filtrate decompression is concentrated into the thick paste shape, adds water and dilutes in right amount, filters, it is an amount of to add edible essence, steviosin and antiseptic again, regulates pH value to prescribed limit, adds water, stir evenly, leave standstill, filter, embedding, sterilization makes oral liquid.
The oral liquid of making adds proper adjuvant through after concentrating, and can be made into capsule or tablet.
An important feature of the present invention is to contain the multiple composition that can improve the human body body's immunity in the medicament, and effective mediator's body immunity function improves the ability of human body self resist the disease.
Clinical drug of the present invention uses the result to show to have following advantage:
What (1) the present invention selected for use is to be raw material with the plant amedica, and each component meets the pharmaceutical control law regulation.Utilize the comprehensive function treatment of the Chinese medicine of respectively distinguishing the flavor of, nontoxic to human body.
(2) the present invention not only can prevent and treatment shows as drained, weakness of QI Mental fatigue, aversion to cold and cold limbs, insomnia forgetfulness to the ill; Or impotence and seminal emission, or the sun loss of fecundity that declines, loose stool and diarrhea, very then aqueous-grainy diarrhea, or incontinence of urine, or waist knee joint weakness, edema of lower limbs, light red tongue moist and slippery fur, the chronic fatigue syndrome that deep-slow pulse is unable improves the effect of human body self immunologic function in addition, plays the effect for the treatment of both the principal and secondary aspects of a disease.
For the treatment mechanism and the effect of medicine of the present invention are described, at first done the experimentation of serial pharmacodynamics aspect, the result is as follows:
1, the experimentation of oral liquid of the present invention (being called for short SFS) anti-stress
Method: adopt and set up the animal model of forcing cold water swimming simulation confirmed fatigue pathogenic process, from stress angle, when observation stress cause fatigue of animals, its substantially behavior and neuroendocrine system variation and to the influence of this variation, tentatively inquire into the mechanism of SFS treatment confirmed fatigue.The result: experimental result shows forces cold water swimming that spontaneous activity in mice is reduced, and depressed tendency occurs; Power exhausts swimming time and shortens physically-draining; Epinephrine in the serum (E), dopamine (DA), 5-hydroxy tryptamine (5-HT) content raise, adrenal gland's ascorbic acid content reduces, these are similar with the lab testing result to the performance of confirmed fatigue patient symptom, and SFS can regulate above-mentioned variation, shows that it has anti-stress, antifatigue effect.Conclusion: anti-stress and resisting fatigue are the important mechanism places of SFS treatment chronic fatigue syndrome.
2, oral liquid of the present invention is to the influence of monoamines content of material variation in confirmed fatigue animal pattern blood plasma and the cerebral tissue
Method: on the basis of using combined stress factor development confirmed fatigue animal pattern, monoamines content of material in animal pattern blood plasma and the cerebral tissue is detected, and observed the regulating action of SFS to such material.The result: the variation of monoamines content of material in blood and the cerebral tissue has appearred in animal pattern, and these variations may be one of pathomechanisms of chronic fatigue syndrome generation.Conclusion: the SFS oral liquid may be by improving the variation of these monoamines content of material, the stress state of tired mice body of relieve chronic and psychology, thereby the recovery of promotion fatigue state.
3, the experimentation of oral liquid treatment insomnia of the present invention
By SFS calmness, hypnosis, the anticonvulsant action of mice are studied.The result: the SFS oral liquid can suppress spontaneous activity in mice, and the influence and the pentobarbital sodium of mice sleep had synergism, the effect of antagonism strychnine nitrate convulsive attack is arranged, and dosage is big more, acts on obvious more.Conclusion: the SFS oral liquid has tangible calmness, hypnosis, anticonvulsant action, so can be used for the insomniac of deficiency of the liver and kindey, hyperactivity of fire caused by deficiency of YIN.
4, oral liquid of the present invention is to the influence of mice IL_2-IFN and NK cytoactive
Method: research SFS oral liquid is in vivo and in vitro to the influence of mouse boosting cell IL-2 and NK cytoactive, strengthens in vivo that new castle disease virus induces IFN and in the external effect that directly induces IFN.The result: the SFS oral liquid can make inside and outside mouse boosting cell IL-2 and NK cytoactive increase, and and with concentration certain relation is arranged, SFS concentration is 0.1% and 0.01% o'clock, IL-2 active and NK cytoactive and matched group comparison, difference has significance.With 0.1% o'clock, IL-2 and NK cytoactive were the highest, can significantly strengthen the effect that new castle disease virus induces IFN, at the external IFN that directly induces, with matched group notable difference were arranged.Conclusion: the SFS oral liquid can improve the mice body's immunity.
5, oral liquid of the present invention improves the experimentation of mouse movement ability
Method: exhaust swimming time by variation, the power of mice being carried out swimming with a load attached to the body training back detection blood lactic acid.The result: obviously raising power of SFS oral liquid exhausts swimming time, reduces the blood lactic acid content.Conclusion: the SFS oral liquid has the mouse movement ability of raising and antifatigue effect.
6, oral liquid of the present invention is to the influence of the functional hormone of animality
Method: make male rat castration model, prepared male mice irritability sexual disorder model simultaneously, the SFS oral liquid gastric infusion of dosage varies in size, and compare with FUFANG EJIAO JIANG, observed influence to castration male rat sexual function, sexual organ's weight, serum gonadal hormone and mice irritability sexual disorder.The result: the SFS oral liquid can obviously improve the sexual function and the male rat serum sex hormone level of castration male rat, and mice irritability sexual disorder is had obvious recovery.Conclusion: the SFS oral liquid has the functional functions of hormones of the animality of raising.
For verifying medicine of the present invention to chronic fatigue syndrome prophylactic treatment effect, the present invention is through the clinical observation of 178 routine systems, and case is from section office such as Guangzhou General Hospital Guangzhou Military Command's outpatient service, Neurology Department, intracardiac sections.Wherein, male's 46 examples, women's 132 examples; 6 months～1 year 111 examples of the course of disease (from making a definite diagnosis), 67 examples more than 2 years; Age is less than 30 years old person's 28 example, 31～40 years old 61 example, and 41～50 years old 42 example, 47 examples more than 50 years old, the mean age is 43.28 years old.Among the oral liquid treatment group 114 routine patients of the present invention, male's 30 examples, women's 84 examples; 6 months～1 year 76 examples of the course of disease (from making a definite diagnosis), 38 examples more than 2 years; Age is less than 30 years old person's 19 example, 31～40 years old 41 example, and 41～50 years old 26 example, 28 examples more than 50 years old, the mean age is 42.91 years old.Among the FUFANG EJIAO JIANG matched group 64 routine patients, male's 15 examples, women's 49 examples; 6 months～1 year 35 examples of the course of disease (from making a definite diagnosis), 29 examples more than 2 years; Age is less than 30 years old person's 10 example, 31～40 years old 23 example, and 41～50 years old 15 example, 16 examples more than 50 years old, the mean age is 43.93 years old.Two groups at aspect there was no significant differences (P＞0.05) such as sex, age, the course of disease, symptom, sign, lab testings, has comparability.
Instructions of taking: oral, 3 times on the one, one time 1.This product is put for a long time can have trace muddy, faces with preceding jolting to get final product.
According to efficacy assessment standard, 114 routine patients are behind clothes oral liquid treatment of the present invention, and produce effects 35 examples account for 30.70%; Effective 64 examples account for 56.14%; Invalid 15 examples account for 13.16%; Total effective rate is 86.84%; According to efficacy assessment standard, 64 routine patients are behind clothes compound ass-hide gelatin oral liquid treatment, and produce effects 9 examples account for 14.06%; Effective 33 examples account for 51.56%; Invalid 22 examples account for 34.38%; Total effective rate is 65.67%, and treatment back curative effect is handled by statistics, and oral liquid of the present invention and FUFANG EJIAO JIANG oral liquid relatively have notable difference P＜0.01, and oral liquid curative effect promptly of the present invention is obviously than the good P of FUFANG EJIAO JIANG＜0.01.Clinical test results such as following table:
| Grouping | Produce effects | Effectively | Invalid | X 2Value | The P value |
| FUFANG EJIAO JIANG | 9 | 33 | 22 | 13.63 | ＜0.01 |
| The SFS oral liquid | 35 | 64 | 15 |
Show that from the result of last table SFS is more effective than FUFANG EJIAO JIANG to the therapeutic effect of chronic fatigue syndrome.
Embodiment 1
Take by weighing raw material (gram) by following proportioning:
Colla cornus cervi 15 Colla Plastri Testudinis 15 Colla Corii Asini 15 Radix Ginseng Rubra 15
Herba Epimedii 15 Herba Cistanches 15 Fructus Amomis 10 Fructus Lyciis 10
Production method is as follows:
More than eight flavors, with Colla cornus cervi, Colla Plastri Testudinis, Colla Corii Asini add (weight ratio) behind 3 times of water respectively, water proof melts, the cooling back filters, merging filtrate, container is collected; Radix Ginseng Rubra adds suitable quantity of water and soaks after 8 hours, decocts three times, and 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, merge three times decocting liquid, cooled and filtered, container is collected; After Herba Epimedii, Herba Cistanches, Fructus Amomi, Fructus Lycii merging add suitable quantity of water together, decoct three times, 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, merge three times decocting liquid, cooled and filtered, container is collected; Above-mentioned five parts of medicinal liquids are merged together, be concentrated into about 500ml, add ethanol 1250ml, stir evenly, left standstill 24 hours, filter, filtrate decompression is concentrated into the thick paste shape, adds water and dilutes in right amount, filters, it is an amount of to add edible essence, steviosin and antiseptic again, regulates pH value to prescribed limit, adds water to 100ml, stir evenly, leave standstill, filter, embedding, sterilization makes oral liquid.
Embodiment 2
Take by weighing raw material (gram) by following proportioning:
Colla cornus cervi 15 Colla Plastri Testudinis 15 Colla Corii Asini 15 Radix Ginseng Rubra 15
Herba Epimedii 15 Herba Cistanches 15 Fructus Amomis 10 Fructus Lyciis 10
Production method is as follows:
More than eight flavors, with Colla cornus cervi, Colla Plastri Testudinis, Colla Corii Asini add (weight ratio) behind 3 times of water respectively, water proof melts, the cooling back filters, merging filtrate, container is collected; Radix Ginseng Rubra adds suitable quantity of water and soaks after 8 hours, decocts three times, and 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, merge three times decocting liquid, cooled and filtered, container is collected; After Herba Epimedii, Herba Cistanches, Fructus Amomi, Fructus Lycii merging add suitable quantity of water together, decoct three times, 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, merge three times decocting liquid, cooled and filtered, container is collected; Above-mentioned five parts of medicinal liquids are merged together, be concentrated into about 500ml, add ethanol 1250ml, stir evenly, left standstill 24 hours, filter, filtrate decompression is concentrated into the thick paste shape, adds water and dilutes in right amount, filters, it is an amount of to add edible essence, steviosin and antiseptic again, regulates pH value to prescribed limit, adds water to 100ml, stir evenly, leave standstill, filter, concentrate, add proper adjuvant, make tablet.
Claims (4)
1, the medicine of a kind of prevention and treatment chronic fatigue syndrome is characterized in that it is the medicament of being made by the following weight proportion raw material:
Colla cornus cervi 10～18 Colla Plastri Testudinis 10～20 Colla Corii Asini 10～20 Radix Ginseng Rubra 12～18
Herba Epimedii 12～20 Herba Cistanches 10～20 Fructus Amomis 8～12 Fructus Lyciis 8～12.
2, the medicine of prevention according to claim 1 and treatment chronic fatigue syndrome, wherein the weight proportion of each raw material is:
Colla cornus cervi 12～15 Colla Plastri Testudinis 12～18 Colla Corii Asini 12～15 Radix Ginseng Rubra 15～18
Herba Epimedii 14～16 Herba Cistanches 14～16 Fructus Amomis 8～12 Fructus Lyciis 8～12.
3, the medicine of prevention according to claim 2 and treatment chronic fatigue syndrome, wherein the weight proportion of each raw material is:
Colla cornus cervi 15 Colla Plastri Testudinis 15 Colla Corii Asini 15 Radix Ginseng Rubra 15
Herba Epimedii 15 Herba Cistanches 15 Fructus Amomis 10 Fructus Lyciis 10.
4, the medicine of prevention according to claim 1 and treatment chronic fatigue syndrome is characterized in that said medicament is oral liquid, capsule or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031469671A CN1240430C (en) | 2003-09-27 | 2003-09-27 | Medicine for preventing and treating chronic exhaustion syndrome and preparing mthod thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031469671A CN1240430C (en) | 2003-09-27 | 2003-09-27 | Medicine for preventing and treating chronic exhaustion syndrome and preparing mthod thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1528381A CN1528381A (en) | 2004-09-15 |
| CN1240430C true CN1240430C (en) | 2006-02-08 |
Family
ID=34286702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031469671A Expired - Fee Related CN1240430C (en) | 2003-09-27 | 2003-09-27 | Medicine for preventing and treating chronic exhaustion syndrome and preparing mthod thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1240430C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103893577B (en) * | 2014-04-04 | 2017-04-05 | 重庆市中药研究院 | A kind of compound gastrodia elata f. glauca tablet, preparation method and applications |
| CN104083404B (en) * | 2014-08-01 | 2015-07-29 | 李江红 | A kind of antidotal Chinese medicine composition |
| CN106074974A (en) * | 2016-07-19 | 2016-11-09 | 成都嘉宝祥生物科技有限公司 | A kind of compositions improving immunity |
-
2003
- 2003-09-27 CN CNB031469671A patent/CN1240430C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1528381A (en) | 2004-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1245187C (en) | Medicine for treating eye disease caused by visceral disease | |
| CN1814167A (en) | Health-care for diabetes | |
| CN101053621A (en) | Traditional Chinese medicinal composition for treating obesity and its preparation method | |
| CN101744924A (en) | Multiple-effect Chinese herbal medicine compound of bacterial diseases of turbot | |
| CN100586465C (en) | Chinese medicine composition for treating melancholia and preparation method thereof | |
| CN1240430C (en) | Medicine for preventing and treating chronic exhaustion syndrome and preparing mthod thereof | |
| CN101590169B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101590167B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101045110A (en) | Medicine composition for treating deficiency of the kidney and its preparing method | |
| CN1422636A (en) | Chinese medicine preparation for treating climacteric metancholia of women | |
| CN101647985B (en) | Medicament composition for treating psoriasis | |
| CN1234404C (en) | Medicine for preventing and treating chronic exhaustion syndrome and preparing method thereof | |
| CN101129632A (en) | Medicament with function of nourishing kidney, warming Yang, preserving essence and benefiting element and method of producing the same | |
| CN101590166B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101991757B (en) | Chinese medicinal composition for reinforcing kidney and supporting yang and preparation method thereof | |
| CN1242766C (en) | Medicine for preventing and treating chronic exhaustion syndrome and preparing method thereof | |
| CN1259095C (en) | Brain-quieting hypertension-treating medicine, and its preparing method and use | |
| CN1313112C (en) | Medicinal composition with nourishing and tranquilizing | |
| CN113332327A (en) | Application of American ginseng and astragalus preparation in preparing product for improving immunity | |
| CN102824414A (en) | Medicinal tea used for treating constipation | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN100525783C (en) | Application of Rangoon creeper fruit and its extracts in preparation of medicine for promoting lead expelling | |
| CN102727730B (en) | Traditional Chinese medicinal compound preparation for treating male infertility and its preparation method | |
| CN1231196A (en) | Capsule for promoting male sexual function and preparation process | |
| CN109452653A (en) | Join brain peptide composition and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU UNIVERSITY OF TRADITIONAL CHINESE MEDIC Free format text: FORMER OWNER: SHI SHIDE Effective date: 20081017 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20081017 Address after: No. 232 East Ring Road, Panyu District University, Guangzhou, Guangdong Patentee after: Guangzhou University of Chinese Medicine Address before: Guangzhou City, Guangdong province Liuhua Road No. 111, Genenral Hospital of PLA Guangzhou Military Area, Department of Medical Laboratory Patentee before: Shi Shide |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060208 Termination date: 20100927 |